Le peptide Selank : recherche, données et limites réelles
Recherche cognitive et nootropique
Selank was designed to do something specific: reduce anxiety without sedation. That was the explicit goal of the Russian programme that produced it in the 1990s — the benzodiazepines already worked, and the point was to find something that worked differently. Whether it succeeded is a question the published evidence answers only partially, and that is the honest place to start.
What Selank is
Selank is a synthetic peptide built from tuftsin, a short naturally occurring peptide fragment that comes from an antibody molecule and is normally studied in immune signalling.
As with Semax, the natural fragment on its own is fragile — enzymes break it down almost immediately. The Selank design attaches a Pro-Gly-Pro sequence to the tuftsin core, which stabilises the molecule enough to be studied. It is the same stabilising trick, applied to a completely different parent peptide, by the same research institute.
That shared design lineage is why the two are so often mentioned in the same breath. It is not because they do the same thing.
Where the research points
- GABAergic modulation. The most-cited strand. GABA is the brain’s principal inhibitory signal — the system benzodiazepines act on — and Selank is studied as a modulator of it, though through a different route than that drug class.
- Enkephalinase inhibition. Selank has been shown to inhibit the enzymes that degrade enkephalins, the body’s own short opioid-like signalling peptides. Rather than adding anything, it is studied for slowing the breakdown of what is already there.
- Anxiety models. The Russian clinical work centres on generalised anxiety and neurasthenia, and this is the indication Selank has been used for there.
- Immune and inflammatory signalling. A smaller strand, following naturally from tuftsin’s origins on an antibody.
The honest state of the evidence
Selank sits in the same position as Semax, with slightly less behind it.
It entered clinical use in Russia in the 1990s and is used there for anxiety disorders. Russian trial reports describe a favourable tolerability profile, and the specific claim made for it — anxiolytic activity without the sedation, tolerance and dependence associated with benzodiazepines — is the reason it attracted attention outside Russia at all.
Set against that: the trials are small, largely single-country, mostly published in Russian, and rarely replicated by independent groups elsewhere. No Western regulator has assessed Selank. The compound has a longer human track record than most research peptides and a much thinner one than any drug you could get from a Canadian pharmacy.
A useful test when reading about either compound: does the source distinguish between registered in Russia and proven? Those are different claims, and sources that blur them are usually selling something.
Why it is usually studied intranasally
The Russian clinical formulation is a nasal solution, and the published work follows suit. The reasoning is the same as for Semax: peptides cross the blood–brain barrier poorly, and intranasal delivery is studied as a route that reaches the central nervous system along the olfactory pathway rather than through general circulation. We cover the route question in detail in intranasal versus subcutaneous research routes.
Selank alongside Semax
The pairing is common enough in the research community to have acquired a nickname — the Russian nootropic stack. The rationale is that the two act on complementary rather than overlapping systems: Semax on plasticity and neurotrophic signalling, Selank on inhibitory and stress-related signalling. Our Semax vs Selank comparison sets out what actually separates them, and why researchers stack peptides covers the general logic behind pairing compounds this way.
What Selank is not
- Not a benzodiazepine. It is studied as a modulator of the same broad system, but it is not in that drug class and does not share its mechanism.
- Not a sedative. The entire design intent was activity without sedation. Sources describing it as a sleep compound have it wrong; the peptide most associated with sleep architecture in this category is DSIP, which is a different molecule entirely.
- Not approved in Canada. Health Canada has not assessed Selank and it holds no Canadian marketing authorisation.
Vistara Labs stocks Selank 10 mg as a lyophilised powder, shipped from within Canada to every province, with a certificate of analysis available on request. It also appears alongside Semax and Cerebrolysin in our research stacks.
Frequently asked questions
What is Selank?
A synthetic peptide derived from tuftsin, a naturally occurring immune-signalling fragment, with a Pro-Gly-Pro sequence added for stability. It was developed in Russia in the 1990s.
What does the Selank research cover?
Principally GABAergic modulation, inhibition of enkephalin-degrading enzymes, and anxiety models. There is a smaller strand of immune and inflammatory signalling work following from tuftsin’s origins.
Is Selank approved anywhere?
It has been in clinical use in Russia since the 1990s, mainly for generalised anxiety and neurasthenia. It is not approved in Canada, the United States or the European Union, and no Western regulator has assessed it.
Is Selank the same as a benzodiazepine?
No. It is studied as a modulator of GABAergic signalling, which is the broad system that drug class acts on, but Selank is not a benzodiazepine and does not share its mechanism or its dependence profile.
What is the difference between Selank and Semax?
They come from different parent peptides — Selank from tuftsin, Semax from ACTH — and are studied around different systems. Selank sits on the inhibitory and anxiolytic side, Semax on plasticity and attention. They share a research institute and a stabilising design, not a mechanism.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.
References
Selank has been evaluated in small human comparative studies of anxiety-related disorders, not in large multicentre placebo-controlled trials.
- [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]Comparative clinical study; 30 patients on Selank versus 32 on medazepam.
- [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]Comparative clinical study; 60 patients with anxiety or somatoform disorders, Selank versus phenazepam.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
